MEKINIST

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug MEKINIST contains one active pharmaceutical ingredient (API):

1	Trametinib UNII BSB9VJ5TUT - TRAMETINIB DIMETHYL SULFOXIDE
	Trametinib is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity.
	Read more about Trametinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MEKINIST Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EE01		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EE Mitogen-activated protein kinase (MEK) inhibitors
Discover more medicines within L01EE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10382K, 10385N, 10403M, 10405P, 11819C, 11821E
BR	Câmara de Regulação do Mercado de Medicamentos	526517030088202, 526517030088302
CA	Health Products and Food Branch	02409623, 02409658
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	2334-MEE-0716, 2401-MEE-0816
EE	Ravimiamet	1656930, 1656941, 1656952, 1656963, 1656974, 1656985
ES	Centro de información online de medicamentos de la AEMPS	114931002, 114931006
FI	Lääkealan turvallisuus- ja kehittämiskeskus	178273, 374194
FR	Base de données publique des médicaments	61803451, 62348191
GB	Medicines & Healthcare Products Regulatory Agency	310793, 310794, 310799, 310800, 368156, 383739
HK	Department of Health Drug Office	64520, 64521
IE	Health Products Regulatory Authority	88886, 88887
IL	מִשְׂרַד הַבְּרִיאוּת	7826, 7848
IT	Agenzia del Farmaco	043524014, 043524026, 043524038, 043524040, 043524053, 043524065
JP	医薬品医療機器総合機構	4291047F1026, 4291047F2022
LT	Valstybinė vaistų kontrolės tarnyba	1073770, 1073771, 1073772, 1073773, 1073774, 1073775
NL	Z-Index G-Standaard, PRK	127884, 127892
NZ	Medicines and Medical Devices Safety Authority	16550, 16552
PL	Rejestru Produktów Leczniczych	100317573, 100317596
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64448001, W64448002, W64449001, W64449002
SG	Health Sciences Authority	15181P, 15182P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699504092196, 8699504092202, 8699504092226, 8699504092233
US	FDA, National Drug Code	0078-0666, 0078-0668, 0078-1105, 0078-1112, 0078-1161
ZA	Health Products Regulatory Authority	51/32.2/0820